Fujirebio Diagnostics employees in Malvern played a crucial role in developing a new Alzheimer’s blood test. They assessed the performance of the test’s components, determined the optimal ratio for the components, and defined the values for a positive test result. Additionally, the team in Malvern prepared the FDA application for the test, showcasing their expertise in clinical and regulatory sciences. This groundbreaking work highlights the importance of diagnostics in the field of Alzheimer’s research, offering hope for earlier and more accurate detection of the disease.
Read more from inquirer.com
